United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Pharma Industry News GSK wins China approval for Trelegy Ellipta in asthma, expanding respiratory market reach Trelegy Ellipta is now approved for asthma in China, giving GSK dual coverage in COPD and asthma. Find out what this means for respiratory market dynamics. bySrinathJanuary 27, 2026